Clinical trials
catalyst calendar across sponsors →Studies where TENX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 1 expanded access · 4 with posted results
Held by 12 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, Point72 Asset Management, L.P., Qube Research & Technologies Ltd, +7 more) · FINRA short interest 1.9 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Long-Term Open-Label Extension Study of Oral LevosimendanNCT07436689The incidence (i.e., the percentage of patients who experience at least 1 occurrence) of select AE/SAEsOpen-label · Treatment | Phase 3 | Enrolling by invitation | Drug: TNX-103 | Pulmonary Hypertension Associated With HFpEF | 800 | Mar 2029 | ≤ 954 d | 2026-07-20 |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2NCT072883986-Minute Walk Distance (6MWD)Randomized · Quadruple-masked · Treatment | Phase 3 | Recruiting | Drug: TNX-103, Placebo | Pulmonary Hypertension Associated With HFpEF | 540 | 2028-06-30 | in 680 d | 2026-08-19 |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEFNCT05983250Change in Six-minute walk distanceRandomized · Quadruple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: TNX-103, Placebo | Pulmonary Hypertension | 230 | 2026-06-30actual | — | 2026-07-24 |
| Open-Label Rollover Study of Levosimendan in PH-HFpEF PatientsNCT03624010results2026-04-22Clinical SafetyOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Levosimendan | Hypertension Pulmonary Secondary Heart Failure, Right Sided Heart Failure With Normal Ejection Fraction, Heart Failure With Normal Ejection Fraction | 35 | 2023-04-25actual | — | 2026-04-22 |
| Hemodynamic Evaluation of Levosimendan in Patients With PH-HFpEFNCT03541603results2024-05-14Change From Baseline Pulmonary Capillary Wedge Pressure (PCWP) With Bicycle ExerciseRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Levosimendan, Matching Placebo | Hypertension Pulmonary Secondary, Heart Failure, Right Sided, Heart Failure With Normal Ejection Fraction | 44 | 2020-04-07actual | — | 2024-11-20 |
| Levosimendan in Patients With Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery On Cardiopulmonary BypassNCT02025621results2018-05-22Number of Dual Efficacy Endpoint EventsRandomized · Quadruple-masked · Prevention | Phase 3 | Completed | Drug: Levosimendan, Placebo | Coronary Artery Bypass Grafting, Mitral Valve Surgery, Low Cardiac Output Syndrome | 882 | Nov 2016actual | — | 2018-06-21 |
| Safety and Tolerability of Oxycyte in Patients With Traumatic Brain Injury (TBI)NCT00908063Safety and tolerability will be compared between treatment groups as measured by frequency, severity, and type of adverse events and serious adverse events between treatment groups.Randomized · Quadruple-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: futility | Drug: Oxycyte, Normal Saline | Traumatic Brain Injury | 18 | Sep 2014actual | — | 2014-11-13 |
| Study of Oxycyte in Severe Closed Head InjuryNCT00174980results2026-02-24Brain Dialysate Concentration DataOpen-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Low enrollment | Drug: Oxycyte | Traumatic Brain Injury | 9 | Mar 2008actual | — | 2026-02-24 |
| Levosimendan Compassionate Use in Pediatric Patients With Advanced Decompensated Heart FailureNCT02973620expanded access | — | No longer available | Drug: Levosimendan | Heart Decompensation | — | — | — | 2018-05-16 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19